Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00227435 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00227435 is a Phase 1 study that has completed, run by Merck Sharp & Dohme.
The verdict
NCT00227435, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
This study was conducted to determine the safety, tolerance, pharmacokinetics and antiviral activity of val-mCyd at doses ranging from 50 mg to 800 mg per day.
Interventions
- DRUG val-mCyd
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-02 |
| Est. Completion | 2004-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00227435
The ClinicalTrials.gov registry entry for NCT00227435 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which val-mCyd is the first listed.
NCT00227435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00227435 about?
NCT00227435 is a clinical study titled "Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C". This study was conducted to determine the safety, tolerance, pharmacokinetics and antiviral activity of val-mCyd at doses ranging from 50 mg to 800 mg per day.
What is the current status of trial NCT00227435?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-02. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00227435?
The interventions under investigation include: val-mCyd (DRUG).
Who is sponsoring clinical trial NCT00227435?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.